Home・Akciju saraksts・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

292.49 1.8

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

287.02

Max

294.69

Galvenie mērījumi
By Trading Economics
Ienākumi	62M 49M
Pārdošana	12M 64M
P/E Sektora vidējais	30.235 57.002
EPS	2.22
Peļņas marža	76.159
Darbinieki	47
EBITDA	87M 72M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+19.1% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	42M 5.9B
Iepriekšējā atvēršanas cena	290.69
Iepriekšējā slēgšanas cena	292.49

Ziņu noskaņojums

By Acuity

38%

62%

135 / 340 Rangs Healthcare

Ligand Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:46 UTC

News

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

2026. g. 13. aug. 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

2026. g. 12. aug. 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

2026. g. 11. aug. 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

2026. g. 10. aug. 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

2026. g. 7. aug. 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

2026. g. 6. aug. 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

2026. g. 5. aug. 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

2026. g. 3. aug. 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

2026. g. 31. jūl. 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

2026. g. 30. jūl. 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

2026. g. 29. jūl. 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

2026. g. 28. jūl. 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

2026. g. 27. jūl. 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

2026. g. 24. jūl. 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

2026. g. 23. jūl. 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

2026. g. 21. jūl. 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Salīdzinājums

Cenas izmaiņa

Ligand Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

19.1% augšup

Prognoze 12 mēnešiem

Vidējais 350.86 USD 19.1%

Augstākais 390 USD

Zemākais 326 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ligand Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ligand Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

135 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.